These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33059259)

  • 1. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.
    Marima R; Hull R; Dlamini Z; Penny C
    Biomed Pharmacother; 2020 Dec; 132():110829. PubMed ID: 33059259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer.
    Marima R; Hull R; Dlamini Z; Penny C
    Front Oncol; 2020; 10():1693. PubMed ID: 32984047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
    Rolón MJ; Figueroa MI; Sued O; Cahn P
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
    Tasias M; Aldeguer JL
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
    Barragan P; Podzamczer D
    Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The profiling, identification, quantification and analysis of differentially expressed genes (DEGs) in response to drug treatment in lung cancer.
    Marima R; Hull R; Dlamini Z; Penny C
    MethodsX; 2021; 8():101381. PubMed ID: 34430277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
    Simpson KN; Luo MP; Chumney E; Sun E; Brun S; Ashraf T
    HIV Clin Trials; 2004; 5(5):294-304. PubMed ID: 15562370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.
    Pitrak DL; Estes R; Novak RM; Linnares-Diaz M; Tschampa JM
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):659-67. PubMed ID: 21054216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
    Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
    HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.